You are viewing: US Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The US Plasma Fractionation Market was valued at $18207.4 Million in 2026 and projected to reach to $26537.8 Million by 2031, representing a compound annual growth rate of 7.8%. The US plasma fractionation market is positioned for sustained growth through 2031, supported by favorable reimbursement policies, aging demographics, and rising incidence of chronic conditions requiring plasma-derived therapies.

US Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Plasma Fractionation Market Trends and Insights

  • The US market benefits from advanced healthcare infrastructure, high demand for immunoglobulin and albumin therapies, and robust reimbursement frameworks that support plasma-derived product adoption.
  • Strong regulatory oversight by the FDA and established collection networks position the US as a leading global hub for plasma fractionation. Driving growth in the US market are increasing prevalence of immunodeficiency disorders, rising geriatric populations requiring clotting factor therapies, and expanding clinical applications for plasma products.
  • The US plasma fractionation sector is characterized by significant investment in recombinant alternatives and next-generation therapies, alongside growing demand from hospitals and specialty clinics.
  • Between 2026 and 2031, the US market will continue to benefit from technological innovations and strategic partnerships among major fractionation companies. The US maintains its position as a critical market within North America, supported by consistent donor recruitment, stringent quality standards, and favorable pricing dynamics for plasma-derived therapeutics..

Key Market Statistics

  • CAGR (2026-2031) 7.8% CAGR
  • Market Size, 2026 ~USD 18207.4 Million
  • Forecast, 2031 ~USD 26537.8 Million
  • Country US

US Plasma Fractionation Market Overview

Market Valuation Growth :

The US plasma fractionation market is valued at $18,207.4 million in 2026 and is projected to reach $26,537.8 million by 2031, demonstrating strong expansion driven by increasing demand for plasma-derived therapies.

Robust Reimbursement Framework :

The US benefits from well-established Medicare and private insurance reimbursement policies that support widespread adoption of immunoglobulin, albumin, and clotting factor therapies across healthcare facilities.

Advanced Healthcare Infrastructure :

State-of-the-art plasma collection centers, fractionation facilities, and distribution networks across the US enable efficient product availability and support consistent market growth at 7.8% CAGR.

High Demand for Immunotherapies :

Increasing prevalence of immunodeficiency disorders, autoimmune diseases, and bleeding disorders in the US population drives sustained demand for immunoglobulin and albumin-based therapeutic solutions.

US Plasma Fractionation Market Dynamics

  • Healthcare providers increasingly recognize the clinical value of immunoglobulins and albumin products, driving adoption across hospitals, specialty clinics, and home care settings.
  • Regulatory support from the FDA and strong supply chain infrastructure further bolster market expansion.
  • The market's 7.8% CAGR reflects confidence in product efficacy and healthcare system capacity to support plasma fractionation therapies..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • The US plasma fractionation market will grow from $18.2B in 2026 to $26.5B in 2031 at a 7.8% CAGR.
      • The US benefits from FDA regulatory excellence, established plasma collection infrastructure, and strong reimbursement policies.
      • Rising immunodeficiency disorders and aging populations are key growth drivers for the US market through 2031.
      • The US leads North America in plasma fractionation innovation, with significant R&D investment in recombinant and next-generation therapies.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      US Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Plasma Fractionation Manufacturers : Manufacturers need US-specific market data to optimize production capacity, plan facility investments, and align product portfolios with American demand for immunoglobulins, albumin, and clotting factors.
      • Healthcare System Administrators : Hospital networks and healthcare systems require market insights to forecast plasma product procurement needs, negotiate supplier contracts, and budget for immunotherapy programs across US facilities.
      • Pharmaceutical Distributors & Wholesalers : US-based distributors need regional market intelligence to optimize inventory management, identify high-demand therapeutic areas, and plan logistics for plasma-derived product distribution.
      • Investment & Private Equity Firms : Investors evaluating US healthcare opportunities require detailed market sizing and growth projections to assess investment returns in plasma fractionation companies and related infrastructure.
      • Regulatory & Policy Consultants : Consultants advising on US healthcare policy and FDA compliance need market data to inform regulatory strategy, reimbursement advocacy, and product development roadmaps for plasma therapies.

      Reasons to Buy this Report

      • US-Specific Market Sizing : Access precise valuation data for the US market ($18.2B in 2026) with detailed forecasts through 2031, enabling accurate budget allocation and revenue projections for US operations.
      • Reimbursement Landscape Insights : Understand Medicare, Medicaid, and private payer reimbursement policies specific to US plasma fractionation products, critical for pricing strategy and market access planning.
      • Competitive Positioning in US Market : Benchmark your US market performance against regional competitors and identify growth opportunities within the 7.8% CAGR expansion trajectory specific to American healthcare systems.
      • Regulatory and Compliance Framework : Gain insights into FDA regulations, quality standards, and compliance requirements unique to US plasma fractionation manufacturing and distribution operations.
      • Strategic Market Entry Planning : Develop informed US market entry or expansion strategies with data on healthcare infrastructure, distribution channels, and demand drivers specific to American patient populations.

      Frequently asked questions

      What is the current size of the US plasma fractionation market?

      The US plasma fractionation market is estimated at $18,207.4 million in 2026 and is expected to reach $26,537.8 million by 2031.

      What is the projected growth rate for the US plasma fractionation market?

      The US plasma fractionation market is projected to grow at a compound annual growth rate (CAGR) of 7.8% from 2026 to 2031.

      What factors are driving growth in the US plasma fractionation market?

      Key drivers include increasing prevalence of immunodeficiency disorders, an aging population requiring clotting factor therapies, expanding clinical applications, and strong FDA regulatory frameworks supporting product adoption in the US.

      How does the US plasma fractionation market compare to other regions?

      The US represents the largest and most mature plasma fractionation market globally, characterized by advanced infrastructure, robust reimbursement systems, and significant R&D investment compared to other regions.

      What are the main plasma-derived products driving the US market?

      The US market is primarily driven by immunoglobulins, albumin, clotting factors, and fibrinogen products, with growing demand from both hospital and specialty clinic settings.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status